美国1992-2018年分化型甲状腺癌伴远处转移患者疾病特异性生存趋势
这项基于监测、流行病学和最终结果-13癌症登记项目的回顾性队列研究纳入1992-2018年1991例远处转移性分化型甲状腺癌患者,发现总体分化型甲状腺癌10年疾病特异性生存率随时间提高,但远处转移性分化型甲状腺癌10年疾病特异性生存率无变化(50.2%、47.3%、52.4%,p=0.48)。非手术治疗率(每年平均增加1.3%)和无/未知治疗率(每年平均增加1.9%)随时间上升,在65-79岁和≥80岁患者中最高。
要点
- 远处转移性分化型甲状腺癌10年疾病特异性生存率无变化(50.2%、47.3%、52.4%,p=0.48)。
- 年龄≥65岁者10年疾病特异性生存率为28.1%,非手术联合外照射和/或系统治疗者为6.0%。
- 1992-2018年非手术治疗率每年平均增加1.3%,无/未知治疗率每年平均增加1.9%。
核心结论
- 过去三十年间远处转移性分化型甲状腺癌患者的疾病特异性生存率无改善。
- 随时间推移,接受非手术治疗或无/未知治疗的患者比例增加,在年龄最大患者中最高。
研究设计与样本
- 基于监测、流行病学和最终结果-13癌症登记项目的基于人群的回顾性队列研究。
- 纳入1992-2018年诊断的1991例远处转移性分化型甲状腺癌患者(69.7%白人,58.0%女性,47.5%年龄≥65岁)。
- 使用多变量逻辑回归和Cox回归分析疾病特异性生存和管理相关因素,采用对数线性回归计算治疗模式的年度百分比变化。
主要发现
- 总体分化型甲状腺癌10年疾病特异性生存率随时间提高:1992-1998年诊断者95.4%,1999-2008年诊断者96.6%,2009-2018年诊断者97.3%(p<0.01)。
- 远处转移性分化型甲状腺癌10年疾病特异性生存率无变化:1992-1998年诊断者50.2%,1999-2008年诊断者47.3%,2009-2018年诊断者52.4%(p=0.48)。
- 10年疾病特异性生存率在年龄≥65岁患者中为28.1%,在接受外照射和/或系统治疗的非手术治疗患者中为6.0%,在无/未知治疗患者中为32.8%。
- 多变量分析中,嗜酸细胞癌、年龄65-79岁和≥80岁、男性、淋巴结阳性疾病、较大肿瘤尺寸、非手术治疗和无/未知治疗与甲状腺癌死亡风险增加相关。
- 1992-2018年间,非手术治疗率每年平均增加1.3%(1992-1998年22.9% vs 2009-2018年25.6%,p=0.03),无/未知治疗率每年平均增加1.9%(1992-1998年11.3% vs 2009-2018年15.6%,p=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Differentiated thyroid cancer (DTC) is associated with an excellent prognosis, but patients with distant metastatic DTC have a 10-year disease-specific survival (DSS) of just 50%. The incidence of distant metastatic DTC has steadily increased in the United States since the 1980s. The aim of this study was to examine trends in survival and treatment for patients with distant metastatic DTC. Methods: In this population-based, retrospective cohort study, patients with distant metastatic DTC were identified from the Surveillance, Epidemiology, and End Results-13 cancer registry program. Multivariable logistic and Cox regression analyses were used to examine factors associated with DSS and management. Annual percentage changes in treatment patterns were calculated using log-linear regression. Results: During 1992-2018, 1991 patients (69.7% white, 58.0% female, 47.5% aged ≥65 years) were diagnosed with distant metastatic DTC. Papillary thyroid cancer was the most common histological type (74.5%). While the 10-year DSS for overall DTC increased over time (95.4% for patients diagnosed in 1992-1998, 96.6% in 1999-2008, and 97.3% in 2009-2018; p < 0.01), 10-year DSS for DTC with distant metastases did not change (50.2%, 47.3%, and 52.4%, respectively; p = 0.48). Ten-year DSS rates were reduced for patients aged ≥65 years (28.1%), patients undergoing nonsurgical treatment with external beam radiation therapy and/or systemic therapy (6.0%), and patients undergoing no/unknown treatment (32.8%). On multivariable analysis, oncocytic carcinoma, age 65-79 and ≥80 years, male sex, node-positive disease, larger tumor size, nonsurgical treatment, and no/unknown treatment were associated with increased risk of thyroid cancer death. Between 1992 and 2018, the rate of nonsurgical treatment increased, on average, 1.3% per year (1992-1998: 22.9% vs. 2009-2018: 25.6%; p = 0.03), and the rate of patients receiving no/unknown treatment increased 1.9% per year (1992-1998: 11.3% vs. 2009-2018: 15.6%; p = 0.01). Patients aged 65-79 and ≥80 years were more likely than younger patients to receive nonsurgical management or no/unknown treatment. Conclusion: Patients diagnosed with distant metastatic DTC have experienced no improvement in DSS over the past three decades. An increasing proportion of patients diagnosed with distant metastatic DTC are receiving nonsurgical treatment or no/unknown treatment over time; the proportion was highest among the oldest patients.
引用
- Wilhelm A, Conroy PC, Calthorpe L, et al. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992-2018. Thyroid. 2022. PMID: 36413032. doi:10.1089/thy.2022.0353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。